

Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

Claim 1 (currently amended): A δ V1-1 peptide selected from the group consisting of δ V1-1 identified as (SEQ ID NO:4), δ V1-2 (SEQ ID NO:5), ψ δ RACK (SEQ ID NO:6), δ V1-5 (SEQ ID NO:7), and derivatives and fragments thereof.

Claim 2 (original): The peptide of claim 1 wherein the derivative is selected from the group consisting of δ V1-1 derivatives identified as SEQ ID NOS:34-48.

Claims 3-4 (canceled)

Claim 5 (original): The peptide of claim 1, wherein the fragment has the sequence selected from the group identified as SEQ ID NOS:49-64.

Claim 6 (canceled)

Claim 7 (original): The peptide according to claim 1, wherein said peptide is recombinantly produced.

Claim 8 (original): The peptide of claim 1, wherein the peptide is chemically synthesized.

Claim 9 (original): The peptide of claim 1, wherein the peptide is encoded by a polynucleotide.

Claims 10-58 (canceled)